Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,307.10",
    "chg": -11.25,
    "chgp": "-0.85%",
    "dir": -1,
    "prev_price": "1,318.35",
    "mcapval": "109,298.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "May 22",
    "curr_time": "",
    "bse_nse_vol": "20.23 lacs",
    "exc_status": "Active",
    "traded_date": "May 22, 2026",
    "traded_date_str": "2026 05 22",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 26.24 vs Industry's 34.53: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-4004573",
        "imagepath": "",
        "date": "2026-05-22 09:21:13",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of 26.24 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands in contrast to the industry’s average of 34.53, indicating the stock is trading at a substantial discount to its sector. This valuation gap suggests that investors are pricing in either a more cautious outlook on the company’s near-term earnings growth or a premium being accorded to other sector constituents. The discount may also reflect concerns over competitive pressures or regulatory challenges within the pharmaceutical space. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratori..."
      },
      {
        "title": "P/E at 26.26 vs Industry's 34.62: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4002387",
        "imagepath": "",
        "date": "2026-05-21 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 26.26 stands well below the industry average of 34.62, signalling a valuation discount that is unusual for a large-cap pharmaceutical player. This divergence suggests that the market is pricing in either a moderation in growth expectations or increased risk relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be trading with a more cautious sentiment. <a href=\"ht..."
      },
      {
        "title": "P/E at 26.5 vs Industry's 34.85: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4000457",
        "imagepath": "",
        "date": "2026-05-20 09:20:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier benchmark index. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures its inclusion in numerous index-tracking funds and ETFs. The company’s market capitalisation of ₹1,10,975.99 crores firmly establishes it as a large-cap entity, a status that underpins its influence on index movements and investor sentiment.</p>\n                <p>Being part of the Nifty 50 confers liquidity advantages and often results in increased institutional participation. This dynamic is evident in Dr Reddys Laboratori..."
      },
      {
        "title": "P/E at 26.44 vs Industry's 35.36: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-3998509",
        "imagepath": "",
        "date": "2026-05-19 09:20:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E of 26.44, which is approximately 25% below the Pharmaceuticals &amp; Biotechnology industry average of 35.36. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. The sector’s elevated P/E reflects strong earnings expectations, but <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys</a> appears to be valued more cautiously. This valuation gap raises the question — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-7345..."
      },
      {
        "title": "P/E at 26.59 vs Industry's 35.37: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-sector-outperformance-and-institutional-shifts-3996327",
        "imagepath": "",
        "date": "2026-05-18 09:20:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Index Membership and Market Capitalisation Significance</strong></p>\n                <p>As a prominent constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in shaping the index’s pharmaceutical and biotechnology representation. With a market capitalisation of approximately ₹1,10,592.05 crores, the company ranks firmly within the large-cap segment, reinforcing its weight and influence on benchmark movements. This stature ensures that any fluctuations in Dr Reddys’ share price reverberate through the index, impacting portfolio allocations of passive funds and institutional investors tracking the Nifty 50.</p>\n                <p>The company’s current share price stands at ₹1,330.60, trading just 3.56% below its 52-week high of ₹1,377.95. This proximity to ..."
      },
      {
        "title": "Dr Reddys Laboratories Gains 3.38%: 5 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-gains-338-5-key-factors-driving-the-weeks-momentum-3994582",
        "imagepath": "",
        "date": "2026-05-16 16:01:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>11 May:</strong> Stock opens at Rs.1,279.70, down 1.05% amid broad market weakness</p>\n                    <p><strong>12 May:</strong> Q4 FY26 results reveal sharp margin compression and 86% profit crash</p>\n                    <p><strong>13 May:</strong> Significant gap down opening at Rs.1,220.20 reflecting market concerns</p>\n                    <p><strong>14 May:</strong> Intraday high surge of 3.15% to Rs.1,302.85, technical and quality grade downgrades announced</p>\n                    <p><strong>15 May:</strong> Intraday high of Rs.1,338.50 with 3.05% gain, technical momentum shifts bullish</p>\n                </div>\n\n                <div class=\"stats-row\">\n                ..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-hold-3994047",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_mojoScore_3994047.png",
        "date": "2026-05-16 10:10:03",
        "description": "Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Surges 3.05% to Day's High of Rs 1338.5 — Outperforms Sector by 2.23 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-305-surge-on-15-may-2026-3992963",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_priceRelatedfactors_3992963.png",
        "date": "2026-05-15 15:30:56",
        "description": "The Sensex slipped 0.16% on 15 Jun 2026 while Dr Reddys Laboratories Ltd gained 3.05%, outperforming its Pharmaceuticals &amp; Biotechnology sector by 2.23 percentage points. This notable single-session gain stands out as a stock-specific event amid a broadly weak market backdrop."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-signal-bullish-outlook-3992055",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DrReddysLaborat_technicaldot_3992055.png",
        "date": "2026-05-15 08:00:23",
        "description": "Dr Reddys Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by positive signals from key technical indicators such as MACD, moving averages, and Bollinger Bands, suggesting an improving price trajectory amid a volatile pharmaceutical sector backdrop."
      }
    ],
    "total": 566,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "18-May-2026",
      "details": "Transcript of Earnings call recordings held on May 12 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "16-May-2026",
      "details": "Intimation of Analyst/Investor meet",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "16-May-2026",
      "details": "Announcement under Regulation 30 (LODR) Regulations 2015 regarding issuance of Press Release viz. Dr. Reddys Laboratories Launches its Generic Semaglutide Injection in Canada.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 26.24 vs Industry's 34.53: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-22 09:21:13

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 26.24 for Dr Reddys Laboratories Ltd stands in contrast to the industry’s average of 34.53, indicating the stock is trading at a substantial discount to its sector. This valuation gap suggests that investors are pricing in either a more cautious outlook on the company’s near-term earnings growth or a premium being accorded to other sector constituents. The discount may also reflect concerns over competitive pressures or regulatory challenges within the pharmaceutical space. Dr Reddys Laboratori...

Read full news article

P/E at 26.26 vs Industry's 34.62: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-21 09:21:09

Valuation Picture: Discount Amidst Sector Premiums

The current P/E ratio of Dr Reddys Laboratories Ltd at 26.26 stands well below the industry average of 34.62, signalling a valuation discount that is unusual for a large-cap pharmaceutical player. This divergence suggests that the market is pricing in either a moderation in growth expectations or increased risk relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys Laboratories Ltd appears to be trading with a more cautious sentiment. Read full news article

P/E at 26.5 vs Industry's 34.85: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-20 09:20:59

Significance of Nifty 50 Membership

As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in representing the Pharmaceuticals & Biotechnology sector within India’s premier benchmark index. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures its inclusion in numerous index-tracking funds and ETFs. The company’s market capitalisation of ₹1,10,975.99 crores firmly establishes it as a large-cap entity, a status that underpins its influence on index movements and investor sentiment.

Being part of the Nifty 50 confers liquidity advantages and often results in increased institutional participation. This dynamic is evident in Dr Reddys Laboratori...

Read full news article

P/E at 26.44 vs Industry's 35.36: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-19 09:20:47

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E of 26.44, which is approximately 25% below the Pharmaceuticals & Biotechnology industry average of 35.36. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. The sector’s elevated P/E reflects strong earnings expectations, but Dr Reddys appears to be valued more cautiously. This valuation gap raises the question — Read full news article

P/E at 26.59 vs Industry's 35.37: What the Data Shows for Dr Reddys Laboratories Ltd

2026-05-18 09:20:52

Index Membership and Market Capitalisation Significance

As a prominent constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in shaping the index’s pharmaceutical and biotechnology representation. With a market capitalisation of approximately ₹1,10,592.05 crores, the company ranks firmly within the large-cap segment, reinforcing its weight and influence on benchmark movements. This stature ensures that any fluctuations in Dr Reddys’ share price reverberate through the index, impacting portfolio allocations of passive funds and institutional investors tracking the Nifty 50.

The company’s current share price stands at ₹1,330.60, trading just 3.56% below its 52-week high of ₹1,377.95. This proximity to ...

Read full news article

Dr Reddys Laboratories Gains 3.38%: 5 Key Factors Driving the Week’s Momentum

2026-05-16 16:01:00

Key Events This Week

11 May: Stock opens at Rs.1,279.70, down 1.05% amid broad market weakness

12 May: Q4 FY26 results reveal sharp margin compression and 86% profit crash

13 May: Significant gap down opening at Rs.1,220.20 reflecting market concerns

14 May: Intraday high surge of 3.15% to Rs.1,302.85, technical and quality grade downgrades announced

15 May: Intraday high of Rs.1,338.50 with 3.05% gain, technical momentum shifts bullish

...

Read full news article

Dr Reddys Laboratories Ltd is Rated Hold

2026-05-16 10:10:03

Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Dr Reddys Laboratories Ltd Surges 3.05% to Day's High of Rs 1338.5 — Outperforms Sector by 2.23 Percentage Points

2026-05-15 15:30:56

The Sensex slipped 0.16% on 15 Jun 2026 while Dr Reddys Laboratories Ltd gained 3.05%, outperforming its Pharmaceuticals & Biotechnology sector by 2.23 percentage points. This notable single-session gain stands out as a stock-specific event amid a broadly weak market backdrop.

Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook

2026-05-15 08:00:23

Dr Reddys Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by positive signals from key technical indicators such as MACD, moving averages, and Bollinger Bands, suggesting an improving price trajectory amid a volatile pharmaceutical sector backdrop.

Read full news article

View All News